Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Translating Research Into Practice (TRIP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03514433
Recruitment Status : Recruiting
First Posted : May 2, 2018
Last Update Posted : July 12, 2019
Sponsor:
Collaborators:
Boston University
University of Massachusetts, Worcester
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Tufts Medical Center
Dana-Farber Cancer Institute
Massachusetts General Hospital
Information provided by (Responsible Party):
Boston Medical Center

Brief Summary:
The TRIP Project aims to overcome barriers to widespread implementation and dissemination of evidence-based practices that will improve the delivery of guideline-concordant care to vulnerable women with breast cancer. To accomplish this goal the study team will create (a) regional patient registries; (b) systematic screening for social barriers to care with a personalized referral plan; and (c) patient navigation services that integrate into one model of care to improve the quality and effectiveness of care delivery, for minority and/or low-income women with breast cancer in Boston.

Condition or disease Intervention/treatment Phase
Cancer, Breast Other: TRIP Patient Navigation Intervention Not Applicable

Detailed Description:

This community-engaged program will demonstrate the feasibility of community-academic partnerships to provide innovations in information sharing and systems implementation targeted to reduce treatment disparities. Patient navigators will be able to utilize the patient database to track their patients throughout their treatment, and receive guidance regarding recommended social resources to patients experiencing hardships via the social determinants platform.

Who: The four Massachusetts CTSA hubs (Boston University, Harvard University, Tufts University, and University of Massachusetts) partnered with the Boston Breast Cancer Equity Coalition, and the 6 hospitals that care for women with breast cancer.

Patient population: 1,100 vulnerable inner city women with risk for delay in breast cancer care. Massachusetts (MA) Cancer Registry data identified the following characteristics of Boston residents with greatest delays in breast cancer treatment: Black, Hispanic, non-English speaking, and public health insurance. Six health care institutions care for >90% of these women:

  1. Beth Israel Deaconess Medical Center (site PI: Ted James, MD)
  2. Boston Medical Center (PI: Tracy Battaglia MD, MPH)
  3. Brigham Women's Hospital/Dana-Farber Cancer Institute (PI: Jennifer Haas MD, MPH)
  4. Faulkner Hospital (site PI: Rachel Freedman, MD)
  5. Massachusetts General Hospital (site PI: Beverly Moy, MD)
  6. Tufts Medical Center (PI: Karen Freund MD, MPH)

UMass Medical Center (PI: Stephenie Lemon, PhD) will play an integral role in the planning and implementation of the TRIP intervention but is not a clinical site.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1100 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A randomized cluster stepped wedge design will be conducted. This pragmatic design involves a sequential, randomized roll-out of the intervention across 6 participating clinical sites or "clusters" over 3 month intervals or "steps". Consistent with a stepped wedge design with one cluster per step, prior to the collection of data in the pre-intervention period, the investigators will generate a set of uniform random numbers for each of the six clusters to assign a starting period for the study intervention. There will be no crossover of patients from usual care to the intervention. That is, patients at each site during the pre-intervention period will experience only usual care and will act as historical controls and those enrolled after the initiation of intervention will experience the intervention.
Masking: Single (Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Translating Research Into Practice: A Regional Collaborative to Reduce Disparities in Breast Cancer Care
Actual Study Start Date : August 6, 2018
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Historical Control
This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout in June 2018. These patients will receive standard patient navigation at their care site and will act as historical controls in comparison to the TRIP experimental group.
Experimental: TRIP Patient Navigation Intervention
This study will be enhancing current patient navigation at the participating 6 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
Other: TRIP Patient Navigation Intervention
The TRIP intervention will replace the current standard of care at the 6 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.




Primary Outcome Measures :
  1. Time-to-treatment post-diagnosis [ Time Frame: Within 90 days of enrollment ]
    The receipt of timely care will be defined as initiation of care within 90 days, as this the shortest delay that has been shown to consistently affect mortality. The time element will be calculated from date of diagnosis (Time0) to date of treatment initiation (Time1) .The date chosen for the Time1 variable will depend on the recommended care plan for each patient, as derived from the chart abstraction and based on patient presentation, including but not limited to stage at diagnosis and co-morbid medical conditions.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   All women with breast cancer diagnosed at a participating study site during the study period will be eligible for inclusion if they meet three study criteria
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. are an adult female 18 years of age or older;
  2. reside in the City of Boston;
  3. have any of the following risk factors for delays in care: are Black and/or Hispanic ethnicity, do not speak English as their primary language, and/or have only public insurance or are uninsured at the time of diagnosis.

Exclusion Criteria:

  1. cancer diagnosis made > 60 days prior to enrollment, such that the ability of the intervention to effect the outcome is limited;
  2. presence of a cognitive impairment such as dementia or delirium from any cause (e.g. metabolic, medication or drug induced), given the unique challenges to their treatment decision making/ adherence and the fact that the intervention would not include the patient directly, but rather the family;
  3. home residence is outside of the city of Boston, Massachusetts.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03514433


Contacts
Layout table for location contacts
Contact: Tracy A Battaglia, MD, MPH 617 638 7428 Tracy.Battaglia@bmc.org
Contact: Nicole L Casanova, BA 617 414 6679 nicole.casanova@bmc.org

Locations
Layout table for location information
United States, Massachusetts
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Karen Freund, MD    617-636-1165    KFreund@tuftsmedicalcenter.org   
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Jennifer Haas, MD MPH    617-724-1832    Jennifer.Haas@MGH.HARVARD.EDU   
Contact: Beverly Moy, MD MPH       bmoy@mgh.harvard.edu   
Boston Medical Center Recruiting
Boston, Massachusetts, United States, 02118
Contact: Sharon Bak    617-638-8036    Sharon.bak@bmc.org   
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Ted James, MD    617-667-5509    ted.james@bidmc.harvard.edu   
Contact: Karolina Ballester    617-667-5509    kballest@bidmc.harvard.edu   
Brigham and Women's Faulkner Hospital Active, not recruiting
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Boston Medical Center
Boston University
University of Massachusetts, Worcester
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Tufts Medical Center
Dana-Farber Cancer Institute
Massachusetts General Hospital
Investigators
Layout table for investigator information
Principal Investigator: Tracy Battaglia, MD., MPH Boston Medical Center

Layout table for additonal information
Responsible Party: Boston Medical Center
ClinicalTrials.gov Identifier: NCT03514433     History of Changes
Other Study ID Numbers: H-37314
1U01TR002070-01 ( U.S. NIH Grant/Contract )
First Posted: May 2, 2018    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Boston Medical Center:
Patient Navigation
Disparity
Social Determinants
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Triptorelin Pamoate
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents